Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: toll-like receptor 3 monoclonal antibodies - Innate Pharma

Drug Profile

Research programme: toll-like receptor 3 monoclonal antibodies - Innate Pharma

Alternative Names: IPH 33; IPH-33-1; IPH-33-2

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innate Pharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Toll-like receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Inflammation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in France (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation(Combination therapy) in France (Parenteral)
  • 10 Jul 2017 Preclinical trials in Cancer in France (Parenteral) before July 2017 (Innate Pharma pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top